REVIEW article
Front. Nutr.
Sec. Nutritional Immunology
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1667863
Iridoids in gardenia fruit: key components in liver disease therapy
Provisionally accepted- Zunyi Medical University, Zunyi, China, Zunyi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Liver diseases pose a serious threat to human health, necessitating the development of safe and effective preventive and therapeutic strategies. Gardenia fruit (GF), the mature fruit of Gardenia jasminoides Ellis, has been widely used in both food and medicinal applications. Over time, GF and its major bioactive constituents, the iridoids, have demonstrated significant potential in the prevention and treatment of various liver diseases. This review first summarizes the structural characteristics and pharmacological activities of the major iridoids in GF from a phytochemical perspective. It then focuses on the therapeutic effects of GF extracts against non-alcoholic fatty liver disease, cholestatic liver disease, acute liver injury, and liver fibrosis. Furthermore, the review provides a comprehensive examination of the multi-target mechanisms by which iridoids mediate their hepatoprotective effects. These mechanisms include the regulation of lipid metabolism, attenuation of cholestasis, suppression of inflammation and oxidative stress, amelioration of mitochondrial dysfunction, modulation of autophagy, as well as anti-fibrotic, anti-hepatocarcinogenic, and detoxification activities. Among these, the inhibition of inflammation and oxidative stress is highlighted as a primary mechanism of action. In addition, this review critically evaluates the current limitations associated with the use of GF and its iridoids in liver disease treatment and discusses potential directions for future research. The aim of this review is to provide theoretical foundations and scientific guidance for the further research and development of GF-based therapeutic agents.
Keywords: gardenia fruit, Iridoids, Liver disease, Pharmacological effects, molecular mechanism
Received: 23 Jul 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Cao, Du, Liu, Li, Luo, Chen, Wang and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lingjie Meng, Zunyi Medical University, Zunyi, China, Zunyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.